International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with cd20-positive b cell ptld: Clues from the ptld-1 trial

Trappe, R. U., Choquet, S., Dierickx, D., Mollee, P., Zaucha, J. M., Dreyling, M. H., Duehrsen, U., Tarella, C., Shpilberg, O., Sender, M., Salles, G., Morschhauser, F., Jaccard, A., Lamy, T., Reinke, P., Neuhaus, R., Lehmkuhl, H., Horst, H. A., Leithaeuser, M., Schlattmann, P., Anagnostopoulos, I., Raphael, M., Riess, H., Leblond, V. and Oertel, S. (2015) International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with cd20-positive b cell ptld: Clues from the ptld-1 trial. American Journal of Transplantation, 15 4: 1091-1100. doi:10.1111/ajt.13086


Author Trappe, R. U.
Choquet, S.
Dierickx, D.
Mollee, P.
Zaucha, J. M.
Dreyling, M. H.
Duehrsen, U.
Tarella, C.
Shpilberg, O.
Sender, M.
Salles, G.
Morschhauser, F.
Jaccard, A.
Lamy, T.
Reinke, P.
Neuhaus, R.
Lehmkuhl, H.
Horst, H. A.
Leithaeuser, M.
Schlattmann, P.
Anagnostopoulos, I.
Raphael, M.
Riess, H.
Leblond, V.
Oertel, S.
Title International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with cd20-positive b cell ptld: Clues from the ptld-1 trial
Journal name American Journal of Transplantation   Check publisher's open access policy
ISSN 1600-6143
1600-6135
Publication date 2015-04
Sub-type Article (original research)
DOI 10.1111/ajt.13086
Volume 15
Issue 4
Start page 1091
End page 1100
Total pages 10
Place of publication Hoboken, NJ United States
Publisher Wiley-Blackwell Publishing
Collection year 2016
Language eng
Abstract Tailoring treatment by patient strata based on the risk of disease progression and treatment toxicity might improve outcomes of patients with posttransplant lymphoproliferative disorder (PTLD). We analysed the cohort of 70 patients treated in the international, multicenter phase II PTLD-1 trial (NCT01458548) to identify such factors. Of the previously published scoring systems in PTLD, the international prognostic index (IPI), the PTLD prognostic index and the Ghobrial score were predictive for overall survival. None of the scoring systems had a considerable effect on the risk for disease progression. Age and ECOG performance status were the baseline variables with the highest prognostic impact in the different scoring systems. Baseline variables not included in the scoring systems that had an impact on overall survival and disease progression were the type of transplant and the response to rituximab at interim staging. Thoracic organ transplant recipients who did not respond to rituximab monotherapy were at particularly high risk for death from disease progression with subsequent CHOP-based chemotherapy. Patients in complete remission after four courses of rituximab and patients in partial remission with low-risk IPI had a low risk of disease progression. We speculate that chemotherapy might not be necessary in this patient cohort.
Keyword Cancer/malignancy
Clinical research/practice
Heart transplantation/cardiology
Hematology/oncology
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 01 May 2015, 18:31:58 EST by System User on behalf of Learning and Research Services (UQ Library)